Ngokuya ngocwaningo olushicilelwe kuNew England Journal of Medicine olushicilelwe ngoJulayi 5, ukusinda kweCabozantinib okuphelele nokuqhubekayo kwiziguli ezine-hepatocellular carcinoma kwakungcono kakhulu kuneqembu le-placebo.
UDkt. Ghassan K. Abou-Alfa ovela eSikhumbuzweni seCancer Sloan Cancer eNew York City nozakwabo bahlele iziguli ezingama-707 ezine-hepatocellular carcinoma ezithuthukile ukuthola i-carbotinib noma i-placebo ehambisanayo ngesilinganiso esingu-2 kuye ku-1. Ababambiqhaza bathole ukwelashwa kwe-sorafenib futhi baba nokuqhubekela phambili kwezifo ngemuva kokwelapha okulodwa noma ngaphezulu kwe-hepatocellular carcinoma.
Ekuhlaziyweni kwaphakathi nohlelo lwesibili, icala likhombisile ukuthi ukusinda okuphelele kwe-carbotinib bekude kakhulu kunalokho kwe-placebo.
Abaphenyi bathola ukuthi ukusinda okuphakathi kwe-carbotinib ne-placebo kwakuyizinyanga eziyi-10.2 nezingu-8.0, ngokulandelana (isilinganiso sengozi yokufa kwakungu-0.76). Okwe-carbotinib ne-placebo, ukusinda okungenamkhawulo kokuqhubeka kwaba izinyanga eziyi-5.2 no-1.9, ngokulandelana. I-68% ne-36% yeziguli eqenjini le-carbotinib neqembu le-placebo lahlangabezana nemicimbi emibi yebanga lesi-3 noma le-4, ngokulandelana. Imicimbi esezingeni eliphakeme kakhulu ukuzwela kwe-erythema yesundu, umfutho wegazi ophakeme, amazinga aphakeme we-aspartate aminotransferase, ukukhathala nohudo, konke okuvame kakhulu nge-carbatinib.
Ababhali babhala, "Ezigulini ezinesifo se-hepatocellular carcinoma eselaphethwe phambilini, ukwelashwa nge-carbotinib kungaholela ekusindeni isikhathi eside nokuphila ngaphandle kwenqubekela phambili kune-placebo."
https://www.drugs.com/news/cabozantinib-improves-survival-advanced-hepatocellular-cancer-75490.html
